We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Analyzing Universal Health's Q3 Earnings: To Buy or Keep Your Cool?
Read MoreHide Full Article
Universal Health Services, Inc. (UHS - Free Report) posted third-quarter 2024 results on Oct. 24, 2024, which were hurt by increased operating expenses due to higher salaries, wages and benefits, other operating expenses, and supplies costs. Nevertheless, the downside was partly offset by revenue growth in the Acute Care Hospital Services and Behavioral Health Care Services segments, attributable to increased patient admissions and adjusted patient days.
Now the question arises whether investors should consider buying stake or hold tight to their current investments. Let us answer that question by assessing UHS’ latest quarterly results and long-term growth prospects.
UHS’ Q3 Results in Detail
Universal Health reported third-quarter adjusted earnings per share of $3.71, which missed the Zacks Consensus Estimate by 1.1%. Nevertheless, the bottom line climbed 45.5% year over year. Net revenues advanced 11.2% year over year to nearly $4 billion. The top line beat the consensus mark by 1.4%.
In the Acute Care Hospital Services unit, adjusted patient days grew 2% year over year. Adjusted patient days in the Behavioral Health Care Services segment increased 1.8% on a same-facility basis. For a detailed analysis, please read our blog on third-quarter earnings: Universal Health Q3 Earnings Miss on Elevated Operating Costs.
Impacts of Rising Expenses on UHS
Despite some improvements in the recent quarters, a shortage of nurses and other medical personnel remains a nationwide issue, impacting the efficient operation of hospitals amid increasing patient volumes. A shortage in the nursing workforce can hinder a hospital's ability to deliver high-quality care, which may compel it to invest a greater amount in employee recruiting and retention initiatives. Such a situation is expected to sustain the pressure of higher costs on Universal Health’s margins in the days ahead.
Total operating costs escalated nearly 8% year over year to $10.5 billion in the first nine months of 2024 due to higher salaries, wages and benefits, other operating expenses, and supplies costs.
UHS’ Long-term Growth Prospects
The top line of Universal Health continues to be driven by increased patient volumes and higher patient days. In the first nine months of 2024, adjusted admissions in its acute care hospitals rose 3.1% year over year on a same-facility basis, while the same in UHS’ behavioral health facilities inched up 0.3%.
The resumption of elective procedures, previously delayed due to the pandemic, is poised to enhance patient volumes and occupancy rates, thus significantly contributing to revenue growth for healthcare facility operators. This resurgence is expected to positively impact Universal Health, as well as its other industry peers such as HCA Healthcare, Inc. (HCA - Free Report) and Tenet Healthcare Corporation (THC - Free Report) .
Universal Health's network of inpatient behavioral healthcare facilities is well-positioned to address the ongoing mental health needs of the American population. As of Sept. 30, 2024, the company maintained a comprehensive treatment network of 27 inpatient acute care hospitals, 334 inpatient behavioral health facilities and 49 outpatient facilities spread across 39 states, Washington DC, the U.K. and Puerto Rico.
The company is committed to expanding and enhancing its services, recruiting top-tier physicians and maintaining rigorous financial and operational oversight, all of which contribute to improved service quality and, ultimately, increased profitability.
UHS Stock’s Price Performance
Universal Health’s shares have gained 34.6% year to date compared with the industry’s 30.4% growth. In comparison with UHS, THC has soared 106.6% in the same time frame and HCA has rallied 31.9%. Meanwhile, the S&P 500 Index has risen 20.5% in the said time frame.
Year-to-Date Price Performance
Image Source: Zacks Investment Research
Mixed Analyst Sentiment for Universal Health
In the past 30 days, the company's 2024 earnings estimates have witnessed downward revisions, while 2025 earnings estimates have witnessed upward revisions.
Image Source: Zacks Investment Research
UHS’ Valuation
The company is cheaply priced compared with the industry average. Currently, UHS is trading at 11.8X forward 12-months earnings, below the industry’s average of 14.15X.
Image Source: Zacks Investment Research
Conclusion
Universal Health’s third-quarter results highlight both its strengths and obstacles for investors to consider. While the company’s earnings missed estimates, growing patient volumes and an extensive treatment network may provide some respite to investors.
UHS’ relatively lower valuation than the industry further enhances the attractiveness of the stock. But a mixed sentiment for estimate revisions reflects the skepticism surrounding the stock. For long-term investors, Universal Health’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a more better entry point.
Image: Bigstock
Analyzing Universal Health's Q3 Earnings: To Buy or Keep Your Cool?
Universal Health Services, Inc. (UHS - Free Report) posted third-quarter 2024 results on Oct. 24, 2024, which were hurt by increased operating expenses due to higher salaries, wages and benefits, other operating expenses, and supplies costs. Nevertheless, the downside was partly offset by revenue growth in the Acute Care Hospital Services and Behavioral Health Care Services segments, attributable to increased patient admissions and adjusted patient days.
Now the question arises whether investors should consider buying stake or hold tight to their current investments. Let us answer that question by assessing UHS’ latest quarterly results and long-term growth prospects.
UHS’ Q3 Results in Detail
Universal Health reported third-quarter adjusted earnings per share of $3.71, which missed the Zacks Consensus Estimate by 1.1%. Nevertheless, the bottom line climbed 45.5% year over year. Net revenues advanced 11.2% year over year to nearly $4 billion. The top line beat the consensus mark by 1.4%.
In the Acute Care Hospital Services unit, adjusted patient days grew 2% year over year. Adjusted patient days in the Behavioral Health Care Services segment increased 1.8% on a same-facility basis. For a detailed analysis, please read our blog on third-quarter earnings: Universal Health Q3 Earnings Miss on Elevated Operating Costs.
Impacts of Rising Expenses on UHS
Despite some improvements in the recent quarters, a shortage of nurses and other medical personnel remains a nationwide issue, impacting the efficient operation of hospitals amid increasing patient volumes. A shortage in the nursing workforce can hinder a hospital's ability to deliver high-quality care, which may compel it to invest a greater amount in employee recruiting and retention initiatives. Such a situation is expected to sustain the pressure of higher costs on Universal Health’s margins in the days ahead.
Total operating costs escalated nearly 8% year over year to $10.5 billion in the first nine months of 2024 due to higher salaries, wages and benefits, other operating expenses, and supplies costs.
UHS’ Long-term Growth Prospects
The top line of Universal Health continues to be driven by increased patient volumes and higher patient days. In the first nine months of 2024, adjusted admissions in its acute care hospitals rose 3.1% year over year on a same-facility basis, while the same in UHS’ behavioral health facilities inched up 0.3%.
The resumption of elective procedures, previously delayed due to the pandemic, is poised to enhance patient volumes and occupancy rates, thus significantly contributing to revenue growth for healthcare facility operators. This resurgence is expected to positively impact Universal Health, as well as its other industry peers such as HCA Healthcare, Inc. (HCA - Free Report) and Tenet Healthcare Corporation (THC - Free Report) .
Universal Health's network of inpatient behavioral healthcare facilities is well-positioned to address the ongoing mental health needs of the American population. As of Sept. 30, 2024, the company maintained a comprehensive treatment network of 27 inpatient acute care hospitals, 334 inpatient behavioral health facilities and 49 outpatient facilities spread across 39 states, Washington DC, the U.K. and Puerto Rico.
The company is committed to expanding and enhancing its services, recruiting top-tier physicians and maintaining rigorous financial and operational oversight, all of which contribute to improved service quality and, ultimately, increased profitability.
UHS Stock’s Price Performance
Universal Health’s shares have gained 34.6% year to date compared with the industry’s 30.4% growth. In comparison with UHS, THC has soared 106.6% in the same time frame and HCA has rallied 31.9%. Meanwhile, the S&P 500 Index has risen 20.5% in the said time frame.
Year-to-Date Price Performance
Image Source: Zacks Investment Research
Mixed Analyst Sentiment for Universal Health
In the past 30 days, the company's 2024 earnings estimates have witnessed downward revisions, while 2025 earnings estimates have witnessed upward revisions.
Image Source: Zacks Investment Research
UHS’ Valuation
The company is cheaply priced compared with the industry average. Currently, UHS is trading at 11.8X forward 12-months earnings, below the industry’s average of 14.15X.
Image Source: Zacks Investment Research
Conclusion
Universal Health’s third-quarter results highlight both its strengths and obstacles for investors to consider. While the company’s earnings missed estimates, growing patient volumes and an extensive treatment network may provide some respite to investors.
UHS’ relatively lower valuation than the industry further enhances the attractiveness of the stock. But a mixed sentiment for estimate revisions reflects the skepticism surrounding the stock. For long-term investors, Universal Health’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a more better entry point.
UHS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.